InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Creates Strategic Medical Billing Partnership, New Revenue Stream
December 15, 2022

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Creates Strategic Medical Billing Partnership, New Revenue Stream

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, announced a new strategic medical billing partnership with Nexus Dental Systems. According to the announcement, Vivos anticipates that the partnership will generate new revenue immediately and will enable the two companies, which currently operate independent billing platforms, to create one of the most comprehensive medical billing services in the dental industry. The new alliance will offer greater access to both in or out-of-network billing with all major medical insurance companies as well as facilitate enhanced case acceptances and insurance billing procedures and reimbursement. “For a long time, medical billing has been a barrier to wide acceptance of dental offices treating breathing and sleep disorders, which is why we have historically offered fee-based out-of-network claims assistance to Vivos providers and their patients,” said Vivos Therapeutics chair and CEO Kirk Huntsman in the press release. “Our Billing Intelligence Service currently achieves a 98% success rate for reimbursement on out-of-network oral appliance claims, which is extremely high. This new relationship will now give Vivos-trained dentists immediate access to some of the highest in-network reimbursement rates in the industry, allowing higher case acceptance for Vivos-trained providers. We believe this will create immediate additional revenue opportunities, not only for Vivos but for providers within each network, while patients pay less out-of-pocket expenses.”

To view the full press release, visit https://ibn.fm/2jaoh

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) as well as snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution. It has proven effective in the treatment of an estimated 31,000 patients worldwide by more than 1,650 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit www.VivosLife.com.  

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).